title: Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application.
abstract: Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of treatment in different patient categories (first and second line of treatment). However, the results were quite similar despite of different dosage used and the combination with dacarbazine in the first line treatment. We reviewed the result of randomized phase II-III clinical studies testing anti-CTLA-4 antibodies (ipilimumab and tremelimumab) for the treatment of melanoma to focus on practical or scientific questions related to the broad utilization of these products in the clinics. These analyses raised some considerations about the future of these compounds, their potential application, dosage, the importance of the schedule (induction/manteinance compared to induction alone) and their role as adjuvants. Anti-CTLA-4 antibody therapy represents the start of a new era in the treatment of advanced melanoma but we are on the steep slope of the learning curve toward the optimization of their utilization either a single agents or in combination.
authors.affiliation: Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy. paolo.ascierto@gmail.com
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Ann Oncol. 2010 Aug;21(8):1712-1717
references.pmid: 20147741
references.citation: J Transl Med. 2010 Apr 20;8:38
references.pmid: 20406483
references.citation: Clin Cancer Res. 2010 May 15;16(10):2861-71
references.pmid: 20460488
references.citation: Invest New Drugs. 2011 Jun;29(3):489-98
references.pmid: 20082117
references.citation: Nature. 1999 Jan 21;397(6716):263-6
references.pmid: 9930702
references.citation: Semin Oncol. 2010 Oct;37(5):473-84
references.pmid: 21074063
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1075-81
references.pmid: 19139427
references.citation: Cancer. 2010 Apr 1;116(7):1767-75
references.pmid: 20143434
references.citation: J Oncol Pharm Pract. 2012 Jun;18(2):287-92
references.pmid: 21807763
references.citation: J Immunother. 2009 Apr;32(3):322-4
references.pmid: 19242368
references.citation: Cancer Res. 2011 Aug 15;71(16):5445-54
references.pmid: 21708958
references.citation: Lancet Oncol. 2010 Feb;11(2):155-64
references.pmid: 20004617
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: Clin Cancer Res. 2010 Feb 1;16(3):1042-8
references.pmid: 20086001
references.citation: Clin Cancer Res. 2010 Jul 1;16(13):3485-94
references.pmid: 20479064
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92
references.pmid: 18818309